Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): An open-label, randomised, phase 3 trial

Helena M. Earl*, Louise Hiller, Janet A. Dunn, Clare Blenkinsop, Louise Grybowicz, Anne Laure Vallier, Jean Abraham, Jeremy Thomas, Elena Provenzano, Luke Hughes-Davies, Ioannis Gounaris, Karen McAdam, Stephen Chan, Rizvana Ahmad, Tamas Hickish, Stephen Houston, Daniel Rea, John Bartlett, Carlos Caldas, David A. CameronLarry Hayward, I. Craig Henderson, Luca Gianni, Mark F. Brady, Xavier Pivot

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

89 Citations (Scopus)
134 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): An open-label, randomised, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences